Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis

Arthritis and Rheumatism

Volumn 54, Issue 11, 2006, Pages 3452-3464

  Funk, Janet L ^a,c   Frye, Jennifer B ^a   Oyarzo, Janice N ^a   Kuscuoglu, Nesrin ^a   Wilson, Jonathan ^a   McCaffrey, Gwen ^a   Stafford, Gregory ^a   Chen, Guanjie ^a   Lantz, R Clark ^a   Jolad, Shivanand D ^a   Sólyom, Aniko M ^b   Kiela, Pawel R ^b   Timmermann, Barbara N ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BONE MORPHOGENETIC PROTEIN 4; CATHEPSIN K; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; COLLAGEN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C6; COMPLEMENT FACTOR I; CYCLOOXYGENASE 2; DIPEPTIDYL PEPTIDASE I; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; LEUKOTRIENE C4 SYNTHASE; MACROPHAGE ELASTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; PROCOLLAGEN; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROTEOCHONDROITIN SULFATE; STROMELYSIN; TOLL LIKE RECEPTOR 1; TURMERIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GRANULOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; JOINT DESTRUCTION; JOINT SWELLING; MICROARRAY ANALYSIS; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

ANIMALS; ANTIOXIDANTS; ARTHRITIS, EXPERIMENTAL; BACTERIAL OUTER MEMBRANE PROTEINS; CURCUMA; DIETARY SUPPLEMENTS; DINOPROSTONE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GRANULOMA; JOINTS; LIVER; MONOCYTES; NEUTROPHILS; NF-KAPPA B; OSTEOCLASTS; PLANT EXTRACTS; RATS; RATS, INBRED LEW; RHIZOME; SPLEEN; STREPTOCOCCUS;

EID: 33750930911     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22180     Document Type: Article

References (41)

1. Foltz-Gray D. Alternative treatments for arthritis. Atlanta: Arthritis Foundation; 2005. p. 231-33.
2. Weil A. Natural health, natural medicine. New York: Houghton Mifflin; 1995. p. 381.
3. Underwood A. Life after Vioxx. Newsweek [article online]. January 31, 2005. URL: http://www.msnbc.msn.com/id/6856959/site/newsweek/.
4. Marcus DM, Grollman AP. Botanical medicines: the need for new regulations. N Engl J Med 2002;347:2073-6.
5. Swanson CA. Suggested guidelines for articles about botanical dietary supplements. Am J Clin Nutr 2002;75:8-10.
6. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980;71:632-4.
7. Banerjee M, Tripathi LM, Srivastava VM, Puri A, Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 2003;25:213-24.
8. Joe B, Rao UJ, Lokesh BR. Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Mol Cell Biochem 1997;169:125-34.
9. Mukhopadhyay A, Basu N, Ghatak N, Gujral PK. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 1982;12:508-15.
10. Aggarwal BB, Kumar A, Aggarwal MS, Shishodia S. Curcumin derived from turmeric (curcuma longa): a spice for all seasons. In: Bagchi D, Preus HG, editors. Phytopharmaceuticals in cancer chemoprevention. Boca Raton (FL): CRC Press; 2004. p. 349-87.
11. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine 2005;12:445-52.
12. Funk JL, Oyarzo JN, Frye JB, Chen G, Lantz RC, Jolad SD, et al. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod 2006;69:351-5.
13. Funk JL, Chen J, Downey KJ, Davee S, Stafford G. Blockade of parathyroid hormone-related protein prevents joint destruction and granuloma formation in streptococcal cell wall-induced arthritis. Arthritis Rheum 2003;48:1721-31.
14. Song X, Zeng L, Jin W, Thompson J, Mizel DE, Lei K, et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999;190:535-42.
15. Geratz JD, Tidwell RR, Schwab JH, Anderle SK, Pryzwansky KB. Sequential events in the pathogenesis of SCW-induced arthritis and their modulation by bis(5-amidino-2-benzimidazolyl)methane (BABIM). Am J Pathol 1990;136:909-21.
16. Funk JL, Lausier J, Moser AH, Shigenaga JK, Huling S, Nissenson R, et al. Endotoxin induces parathyroid hormone-related protein gene expression in splenic stromal and smooth muscle cells, not in splenic lymphocytes. Endocrinology 1995;136:3412-21.
17. Chen J, Downey KJ, Funk JL. Estrogen inhibits T-cell mediated arthritis and RANK-mediated bone resorption in rats with SCW-induced arthritis [abstract]. J Bone Miner Res 2002;17: S387.
18. Jiang H, Timmermann BN, Gang DR. Use of LC-electrospray ionization tandem mass spectrometry to identify diarylheptanoids in turmeric (Curcuma longa L.) rhizome. J Chromatogr A 2006;1111:21-31.
19. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-κ B ligand-induced NF-κ B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004;172:5940-7.
20. Ozaki K, Kawata Y, Amano S, Hanazawa S. Stimulatory effect of curcumin on osteoclast apoptosis. Biochem Pharmacol 2000;59:1577-81.
21. Ozaki K, Takeda H, Iwahashi H, Kitano S, Hanazawa S. NF-κB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett 1997;410:297-300.
22. Subramaniam S, Stansberg C, Cunningham C. The interleukin 1 receptor family. Dev Comp Immunol 2004;28:415-28.
23. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-7.
24. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002;61 Suppl 2:ii84-6.
25. Quandt SA, Chen H, Grzywacz JG, Bell RA, Lang W, Arcury TA. Use of complementary and alternative medicine by persons with arthritis: results of the National Health Interview Survey. Arthritis Rheum 2005;53:748-55.
26. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. Role of the proteosome and NF-κB in SCW-induced polyarthritis. Proc Natl Acad Sci U S A 1998;95:15671-6.
27. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble TNF receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
28. Freireich EJ, Gehan EA, Ral DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
29. Food and Drug Administration. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/cder/guidance/5541fnl.pdf.
30. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900.
31. Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, et al. The effect of dexamethasone on the expression of activated NF-κ B in adjuvant arthritis. Clin Immunol Immunopathol 1997;83:173-8.
32. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, et al. Curcumin blocks cytokine-mediated NF-κ B activation and proinflammatory gene expression by inhibiting inhibitory factor I-κ B kinase activity. J Immunol 1999;163:3474-83.
33. Verma IM. Nuclear factor (NF)-κB proteins: therapeutic targets. Ann Rheum Dis 2004;63 Suppl 2:ii57-61.
34. Roshak AK, Callahan JF, Blake SM. Small-molecule inhibitors of NF-κB for the treatment of inflammatory joint disease. Curr Opin Pharmacol 2002;2:316-21.
35. Firestein GS. NF-κB: Holy Grail for rheumatoid arthritis? [editorial]. Arthritis Rheum 2004;50:2381-6.
36. Sen M. Wnt signalling in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:708-13.
37. Nakamura Y, Nawata M, Wakitani S. Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am J Pathol 2005;167:97-105.
38. Solomon S, Kassahn D, Illges H. The role of the complement and the FcγR system in the pathogenesis of arthritis. Arthritis Res Ther 2005;7:129-35.
39. Nauta AJ, Roos A, Daha MR. A regulatory role for complement in innate immunity and autoimmunity. Int Arch Allergy Immunol 2004;134:310-23.
40. Van de Loo FA, van den Berg WB. Gene therapy for rheumatoid arthritis: lessons from animal models. Rheum Dis Clin North Am 2002;28:127-49.
41. Lam J, Takeshita S, Barker JE, Kanagawa O, Ros FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.